The typical treatment requires starting at a low dose and gradually increasing it every four weeks
Semaglutide, a potent GLP-1R activator (GLP1-RA), is recommended by diabetes associations to improve glycemic control in patients with T2D and as a first-line therapy in established atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors to reduce the risk of major adverse cardiovascular events (MACE), i.e., myocardial infarction, stroke and cardiovascular death [5,6]
doi: 10.1056/NEJMoa012908
Wegovy for weight loss is designed to increase dosage over time to minimize side effects gradually
They also see these drugs as the best choices for lowering glucose and helping with weight loss
GD: Writingreview and editing, Writingoriginal draft, Visualization, Funding acquisition